ResearcherEmory UniversityActive in the last 2 years

Robert Donald Harvey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4217-1313; OpenAlex author ID A5043235685. Sources: ClinicalTrials.gov.

Their work

Papers: 1 (first author 1, last author 0)
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2014: 1 trial · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 1

Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer. First author DOI 10.1093/oncolo/oyaf284 ↗

Trials 1

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Principal investigator NCT02273752 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Taofeek Kunle Owonikoko · 1 shared paper, 2025 · strength 0.23
- Paper Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cance… DOI 10.1093/oncolo/oyaf284 ↗
Olatunji Boladale Alese · 1 shared paper, 2025 · strength 0.23
- Paper Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cance… DOI 10.1093/oncolo/oyaf284 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.